Susan Escudier, MD, FACP, explains some of the ways Texas Oncology mitigates financial toxicity and improve clinical trial access for underserved patients.

Meetings designed to distribute grant money to fund research were canceled as part of a communications freeze at health agencies.

Just down the street from the two hospitals, the region's medical school — Texas ... Cancer Research and Treatment Center among the "100 Hospitals and Health Systems with Great Oncology Programs." ...

Travis Brewer, vice president of payer and public health strategy at Texas Oncology, discusses the role of biosimilars in making cancer care more affordable and accessible, as well as the need for ...

Only one state has adopted a similar approach to cancer care as one first proposed by a Texas A&M University professor.

Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) has announced the resumption of patient enrollment in a Phase 1/2 clinical trial evaluating seclidemstat combined with azacitidine for myelodysplastic ...

In a previous clinical trial, the HEROS study ... professor of pediatrics—hematology and oncology at Baylor and pediatric oncologist at Texas Children's Cancer Center. The researchers currently ...

A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, ...

The Pediatric Hematology-Oncology Fellowship Program at Texas Children's ... The vast majority of our graduates have gone on to highly successful academic, research, and clinical careers. Our ...